Is clinical proteomics heading towards to "bench to bedside"?

Translational Proteomics

Volumn 1, Issue 1, 2013, Pages 53-56

  Oliveira, Bruno M ^a   Schmitt, Andrea ^b,c   Falkai, Peter ^b   Martins de Souza, Daniel ^b,c,d  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Bench to bedside; Biomarkers; Clinical biomarkers; Mass spectrometry; Proteome; Proteomics

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; PROTEOME; TRANSCRIPTOME;

ACCURACY; ARTICLE; BIOINFORMATICS; DNA MICROARRAY; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PROCESSING; PROTEOMICS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SERIAL ANALYSIS OF GENE EXPRESSION; TRANSCRIPTOMICS;

EID: 84994438819     PISSN: 22129626     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trprot.2013.05.001     Document Type: Article

References (39)

1. Hayashi K, Masuda S, Kimura H. Analyzing global trends of biomarker use in drug interventional clinical studies. Drug Discoveries & Therapeutics 2012;6:102-7.
2. Wery J. Application of proteomics technologies to biomarker discovery and development - challenges and solutions. Current Separations 2007;22:15-7.
3. Tajik P, Bossuyt PM. Genomic markers to tailor treatments: waiting or initiating? Human Genetics 2011;130:15-8.
4. López E, Madero L, López-Pascual J, Latterich M. Clinical proteomics and OMICS clues useful in translational medicine research. Proteome Science 2012;10:35.
5. Ghosh D, Poisson LM. "Omics" data and levels of evidence for biomarker discovery. Genomics 2009;93:13-6.
6. Ng PC, Lam HS. Biomarkers in neonatology: the next generation of tests. Neonatology 2012;102:145-51.
7. Jamesdaniel S, Salvi R, Coling D. Auditory proteomics: methods, accomplishments and challenges. Brain Research 2009;1277:24-36.
8. Graves PR, Haystead TAJ. Molecular biologist's guide to proteomics. Microbiology and Molecular Biology Reviews: MMBR 2002;66:39-63.
9. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science (New York, NY) 1995;270:484-7.
10. Shalon D, Smith SJ, Brown PO. A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Research 1996;6:639-45.
11. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science (New York, NY) 1995;270:467-70.
12. Martins-de-Souza D. Proteomics is not only a biomarker discovery tool. Proteomics - Clinical Applications 2009;3:1136-9.
13. Pandey A, Mann M. Proteomics to study genes and genomes. Nature 2000;405:837-46.
14. Martins-de-Souza D. Is the word "biomarker" being properly used by proteomics research in neuroscience? European Archives of Psychiatry and Clinical Neuroscience 2010;260:561-2.
15. Martins-de-Souza D, Guest PC, Vanattou-Saifoudine N, Harris LW, Bahn S. Proteomic technologies for biomarker studies in psychiatry: advances and needs. International Review of Neurobiology 2011;101:65-94.
16. Serkova NJ, Standiford TJ, Stringer KA. The emerging field of quantitative blood metabolomics for biomarker discovery in critical illnesses. American Journal of Respiratory and Critical Care Medicine 2011;184:647-55.
17. Pearson H. Meet the human metabolome. Nature 2007; 446:8.
18. Pando-Robles RV, Lanz-Mendoza H. The significance of proteomics in public health. Salud Pública de México 2009;51(Suppl. 3):S386-94.
19. Thomas CE, Ganji G. Integration of genomic and metabonomic data in systems biology - are we "there" yet? Current Opinion in Drug Discovery & Development 2006;9:92-100.
20. Fischer R, Trudgian DC, Wright C, Thomas G, Bradbury LA, Brown MA, Bowness P, Kessler BM. Discovery of candidate serum proteomic and metabolomic biomarkers in ankylosing spondylitis. Molecular & Cellular Proteomics: MCP 2012;11. M111.013904.
21. Caudle WM, Bammler TK, Lin Y, Pan S, Zhang J. Using "omics" to define pathogenesis and biomarkers of Parkinson's disease. Expert Review of Neurotherapeutics 2010;10:925-42.
22. Blanchet L, Smolinska A, Attali A, Stoop MP, Ampt KA, van Aken H, Suidgeest E, Tuinstra T, Wijmenga SS, Luider T, Buydens LM. Fusion of metabolomics and proteomics data for biomarkers discovery: case study on the experimental autoimmune encephalomyelitis. BMC Bioinformatics 2011;12:254.
23. McDermott JE, Wang J, Mitchell H, Webb-Robertson BJ, Hafen R, Ramey J, Rodland KD. Challenges in biomarker discovery: combining expert insights with statistical analysis of complex omics data. Expert Opinion on Medical Diagnostics 2013;7:37-51.
24. Gold L, Williams S, Janjic N, Saccomano N, Steele F. Making the cut: untangling clinical protein biomarker discovery and validation. Biomarkers in Medicine 2011;5:189-91.
25. Anderson NL. The human plasma proteome: history, character, and diagnostic prospects. Molecular & Cellular Proteomics 2002;1:845-67.
26. Koutroukides TA, Guest PC, Leweke FM, Bailey DM, Rahmoune H, Bahn S, Martins-de-Souza D. Characterization of the human serum depletome by label-free shotgun proteomics. Journal of Separation Science 2011;34:1621-6.
27. Savino R, Paduano S, Preianò M, Terracciano R. The proteomics big challenge for biomarkers and new drug-targets discovery. International Journal of Molecular Sciences 2012;13:13926-48.
28. Sabel MS, Liu Y, Lubman DM. Proteomics in melanoma biomarker discovery: great potential, many obstacles. International Journal of Proteomics 2011;2011:181890.
29. Abu-Asab MS, Chaouchi M, Alesci S, Galli S, Laassri M, Cheema AK, Atouf F, VanMeter J, Amri H. Biomarkers in the age of omics: time for a systems biology approach. Omics: A Journal of Integrative Biology 2011;15:105-12.
30. Younesi E, Toldo L, Mueller B, Friedrich CM, Novac N, Scheer A, Hofmann-Apitius M, Fluck J. Mining biomarker information in biomedical literature. BMC Medical Informatics and Decision Making 2012;12:148.
31. Fu WJ, Stromberg AJ, Viele K, Carroll RJ, Wu G. Statistics and bioinformatics in nutritional sciences: analysis of complex data in the era of systems biology. The Journal of Nutritional Biochemistry 2010;21:561-72.
32. Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, Lewis S, Currie I. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003;3:36-44.
33. Karp NA, McCormick PS, Russell MR, Lilley KS. Experimental and statistical considerations to avoid false conclusions in proteomics studies using differential in-gel electrophoresis. Molecular & Cellular Proteomics: MCP 2007;6:1354-64.
34. Karp NA, Kreil DP, Lilley KS. Determining a significant change in protein expression with DeCyder during a pair-wise comparison using two-dimensional difference gel electrophoresis. Proteomics 2004;4:1421-32.
35. Karp NA, Lilley KS. Maximising sensitivity for detecting changes in protein expression: experimental design using minimal CyDyes. Proteomics 2005;5:3105-15.
36. Lewis C, Ohlendieck K. Proteomic profiling of naturally protected extraocular muscles from the dystrophin-deficient mdx mouse. Biochemical and Biophysical Research Communications 2010;396:1024-9.
37. Lewis C, Jockusch H, Ohlendieck K. Proteomic profiling of the dystrophin-deficient mdx heart reveals drastically altered levels of key metabolic and contractile proteins. Journal of Biomedicine & Biotechnology 2010;2010:648501.
38. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proceedings of the National Academy of Sciences of the United States of America 2003;100:9440-5.
39. Karp NA, Lilley KS. Design and analysis issues in quantitative proteomics studies. Proteomics 2007;7 (Suppl. 1):42-50.